May University of Galway to lead Horizon Europe project on biodegradable medical implants

University of Galway is to join 18 international research and academic partners in a Horizon Europe funded project to develop new biodegradable vascular implants.

The BIOMEND programme will be led by Dr Ted Vaughan, Associate Professor in Biomedical Engineering and Principal Investigator in the Biomechanics Research Centre at the University of Galway, with his colleague Professor Peter McHugh, and in close partnership with Dr Alexander Kopp, founder of Meotec Gmbh, located in Aachen, Germany, a world-leader in the production of biodegradable metal alloys for medical applications.

Biodegradable materials are a category of biomaterial that gradually degrade when implanted in the body and have the potential to form the basis for the next-generation of endovascular stents, as they can reduce long-term complications associated with existing devices.

Together with the wider BIOMEND consortium, the research team will tackle key technological challenges in the area of biodegradable implants so that they can be safely used in the human body.

Dr Ted Vaughan, Associate Professor in Biomedical Engineering at University of Galway, said: "We are delighted to receive this funding, which allows us to bring together leading experts from across Europe to develop the next-generation of biodegradable implants. Our goal is to develop a range of endovascular stent implants that reduce the risk of long-term complications and improve patient outcomes."

Funded through the Marie Skłodowska-Curie Actions scheme, the BIOMEND project is structured as an integrated research and training programme.

As the proposal lead and BIOMEND training coordinator, Dr Eva Barrett, School of Engineering at University of Galway, explains: “BIOMEND will deliver world-class interdisciplinary training to 15 PhD researchers, who will carry out industry-based doctorates across the BIOMEND network. This will significantly enhance the career development and employment prospects of these researchers, promoting their future development into leading innovators of medical technologies.”

Ends